Claire Alexandre Hart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claire Alexandre Hart has a total of 461 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Brown
Division of Cancer Sciences, University of Manchester, UK
28 shared publications - Noel William Clarke
Department of Surgery, The Christie Hospital NHS Foundation Trust, UK
28 shared publications Vijay A.C. Ramani
Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
5 shared publications- Ashwin Sachdeva
Departments of Surgery and Urology, The Christie and Salford Royal Hospitals; Manchester, UK; Genitourinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK
4 shared publications J. Dwyer
The University of Manchester
4 shared publications- Jaleel Ahmad Miyan
Faculty of Biology, Medicine & Health, Division of Neuroscience & Experimental Psychology, The University of Manchester, Manchester, UK
4 shared publications
Latest Publications
- Open Access
Prognostic Significance of PTEN Loss in Prostate Cancer: A Meta-Analysis of Gleason Grade and Clinical Outcomes
Aims: Prostate cancer (PCa) presents ongoing challenges in differentiating aggressive from indolent disease using traditional biomarkers such as prostate-specific antigen (PSA). The Phosphatase and Tensin Homolog (PTEN), a key tumour suppressor involved in cellular growth regulation, is emerging as a promising biomarker for risk stratification. This meta-analysis aims to evaluate the prognostic significance of PTEN loss in PCa, particularly its relationship with Gleason grade groups (GG), as defined by the ISUP system, and clinical outcomes. Methods: A systematic review and meta-analysis of 16 studies encompassing 11,375 patients was conducted in accordance with PRISMA guidance. Studies included evaluated PTEN loss, stratified by hemizygous and homozygous deletions, and its association with GG and clinical endpoints such as biochemical recurrence and lethal progression. Pooled odds ratios (ORs) and hazard ratios (HRs) were calculated using a random-effects model. Results: PTEN loss was significantly associated with tumour aggressiveness. Compared to GG1 tumours, the odds of PTEN loss were markedly increased in Gleason GG 2 and 3(OR: 2.78, 95% CI: 1.95–3.61) and GG ≥ 4 (OR: 6.35, 95% CI: 5.37–7.33). Homozygous PTEN deletions were more strongly associated with high-grade tumours than hemizygous deletions. Clinically, PTEN loss was predictive of adverse outcomes, including increased risk of biochemical recurrence (HR: 1.78, 95% CI: 1.31–2.25) and lethal progression (HR: 2.57, 95% CI: 1.12–3.95). Conclusion: PTEN loss correlates with higher GG and poorer clinical outcomes in PCa. Incorporating PTEN assessment into clinical decision making could improve risk stratification, guiding early intervention strategies and identifying patients suitable for active surveillance.
Open AccessPrognostic Significance of PTEN Loss in Prostate Cancer: A Meta-Analysis of Gleason Grade and Clinical Outcomes
Aims: Prostate cancer (PCa) presents ongoing challenges in differentiating aggressive from indolent disease using traditional biomarkers such as prostate-specific antigen (PSA). The Phosphatase and Tensin Homolog (PTEN), a key tumour suppressor involved in cellular growth regulation, is emerging as a promising biomarker for risk stratification. This meta-analysis aims to evaluate the prognostic significance of PTEN loss in PCa, particularly its relationship with Gleason grade groups (GG), as defined by the ISUP system, and clinical outcomes. Methods: A systematic review and meta-analysis of 16 studies encompassing 11,375 patients was conducted in accordance with PRISMA guidance. Studies included evaluated PTEN loss, stratified by hemizygous and homozygous deletions, and its association with GG and clinical endpoints such as biochemical recurrence and lethal progression. Pooled odds ratios (ORs) and hazard ratios (HRs) were calculated using a random-effects model. Results: PTEN loss was significantly associated with tumour aggressiveness. Compared to GG1 tumours, the odds of PTEN loss were markedly increased in Gleason GG 2 and 3(OR: 2.78, 95% CI: 1.95–3.61) and GG ≥ 4 (OR: 6.35, 95% CI: 5.37–7.33). Homozygous PTEN deletions were more strongly associated with high-grade tumours than hemizygous deletions. Clinically, PTEN loss was predictive of adverse outcomes, including increased risk of biochemical recurrence (HR: 1.78, 95% CI: 1.31–2.25) and lethal progression (HR: 2.57, 95% CI: 1.12–3.95). Conclusion: PTEN loss correlates with higher GG and poorer clinical outcomes in PCa. Incorporating PTEN assessment into clinical decision making could improve risk stratification, guiding early intervention strategies and identifying patients suitable for active surveillance.
- Open Access
- 10 March 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 150 (9) , 1741-1753
Full fingerprint hyperspectral imaging of prostate cancer tissue microarrays within clinical timeframes using quantum cascade laser microscopy
One of the major limitations for clinical applications of infrared spectroscopic imaging modalities is the acquisition time required to obtain reasonable images of tissues with high spatial resolution and good signal-to-noise ratio (SNR). The time to acquire a reasonable signal to noise spectroscopic scan of a standard microscope slide region of tissue can take many hours. As a trade-off, systems can allow for discrete wavenumber acquisitions, sacrificing potentially vital chemical bands in order to reach specific acquisition targets. Recent instrumentation developments now allow for the full fingerprint imaging of entire microscope slides in under 30 minutes, enabling rapid, high quality spectroscopic imaging of tissues within clinical timeframes without sacrificing frequency bands. Here we compare the data from a novel QCL microscope to an FTIR microscope covering multiple aspects of spectroscopic imaging of a large, clinically relevant, prostate cancer tissue cohort (N = 1281). Comparisons of hyperspectral data acquisition quality in both achieved signal to noise and image contrast alongside the capacity for unsupervised and supervised modelling of tissue constituents are reported. We conclude that it is now possible to collect full fingerprint spectra and derive clinically relevant data in a timeframe suitable for translation into the pathology laboratory without the need to resort to discrete frequency imaging with subsequent loss of information.
- 10 March 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 150 (9) , 1741-1753
Open AccessFull fingerprint hyperspectral imaging of prostate cancer tissue microarrays within clinical timeframes using quantum cascade laser microscopy
One of the major limitations for clinical applications of infrared spectroscopic imaging modalities is the acquisition time required to obtain reasonable images of tissues with high spatial resolution and good signal-to-noise ratio (SNR). The time to acquire a reasonable signal to noise spectroscopic scan of a standard microscope slide region of tissue can take many hours. As a trade-off, systems can allow for discrete wavenumber acquisitions, sacrificing potentially vital chemical bands in order to reach specific acquisition targets. Recent instrumentation developments now allow for the full fingerprint imaging of entire microscope slides in under 30 minutes, enabling rapid, high quality spectroscopic imaging of tissues within clinical timeframes without sacrificing frequency bands. Here we compare the data from a novel QCL microscope to an FTIR microscope covering multiple aspects of spectroscopic imaging of a large, clinically relevant, prostate cancer tissue cohort (N = 1281). Comparisons of hyperspectral data acquisition quality in both achieved signal to noise and image contrast alongside the capacity for unsupervised and supervised modelling of tissue constituents are reported. We conclude that it is now possible to collect full fingerprint spectra and derive clinically relevant data in a timeframe suitable for translation into the pathology laboratory without the need to resort to discrete frequency imaging with subsequent loss of information.
- Open Access
IRF7 impacts on prostate cancer cell survival in response to radiation
Understanding the impact of radiotherapy on the evolution of treatment resistant prostate cancer is critical for selecting effective treatment combinations. Whilst activation of Type 1 interferon signalling is a hallmark of how cells respond to viral infection, in cancer cells, multiple stresses are known to activate this same response. In this study we have evaluated for the first time the changes in the interferon response induced by culturing prostate cancer cells under sphere- forming conditions and following irradiation. We report a conserved upregulated transcript profile for both conditions that is strongly associated with therapeutic resistance and cell survival in vitro and in vivo. The profile includes and is regulated by the Type 1 interferon master regulator IRF7 which, when depleted, delays tumour re-growth following irradiation. We immuno-stained two independent prostate cohorts for IRF7 and found that increased expression, particularly in cases with low PTEN expression, correlated with poor prognosis. To more comprehensively characterise the impact of IRF7 and radiation on cells, RNA-Seq was performed on IRF7 knockdown cells at different radiation doses. We identified a number of biological processes that were IRF7-dependent, including the formation of stem-like cell populations and also therapeutic vulnerabilities. For example, irradiation sensitised surviving cells to either a combination of an IKKε/TBK1 and a MEK inhibitor or treatment with an inhibitor of IDO1, an IRF7- dependent gene. Translationally our work suggests that IRF7 expression can be used to stratify patients who may not benefit from receiving radiotherapy alone but rather may benefit from treatment combinations. In two cohorts treated with radical intent, strong IRF7 staining was associated with disease-specific death implicating this pathway as a convergence point for therapeutic resistance in prostate and potentially other cancer types.
Open AccessIRF7 impacts on prostate cancer cell survival in response to radiation
Understanding the impact of radiotherapy on the evolution of treatment resistant prostate cancer is critical for selecting effective treatment combinations. Whilst activation of Type 1 interferon signalling is a hallmark of how cells respond to viral infection, in cancer cells, multiple stresses are known to activate this same response. In this study we have evaluated for the first time the changes in the interferon response induced by culturing prostate cancer cells under sphere- forming conditions and following irradiation. We report a conserved upregulated transcript profile for both conditions that is strongly associated with therapeutic resistance and cell survival in vitro and in vivo. The profile includes and is regulated by the Type 1 interferon master regulator IRF7 which, when depleted, delays tumour re-growth following irradiation. We immuno-stained two independent prostate cohorts for IRF7 and found that increased expression, particularly in cases with low PTEN expression, correlated with poor prognosis. To more comprehensively characterise the impact of IRF7 and radiation on cells, RNA-Seq was performed on IRF7 knockdown cells at different radiation doses. We identified a number of biological processes that were IRF7-dependent, including the formation of stem-like cell populations and also therapeutic vulnerabilities. For example, irradiation sensitised surviving cells to either a combination of an IKKε/TBK1 and a MEK inhibitor or treatment with an inhibitor of IDO1, an IRF7- dependent gene. Translationally our work suggests that IRF7 expression can be used to stratify patients who may not benefit from receiving radiotherapy alone but rather may benefit from treatment combinations. In two cohorts treated with radical intent, strong IRF7 staining was associated with disease-specific death implicating this pathway as a convergence point for therapeutic resistance in prostate and potentially other cancer types.
- Open Access
- 12 December 2019
- Published by IOP Publishing in Publications of the Astronomical Society of the Pacific
- Vol. 132 (1007) , 014201
Acceleration of Coronal Mass Ejection Plasma in the Low Corona as Measured by the Citizen CATE Experiment
The citizen Continental-America Telescopic Eclipse (CATE) Experiment was a new type of citizen science experiment designed to capture a time sequence of white-light coronal observations during totality from 17:16 to 18:48 UT on 2017 August 21. Using identical instruments the CATE group imaged the inner corona from 1 to 2.1 RSun with 1.″43 pixels at a cadence of 2.1 s. A slow coronal mass ejection (CME) started on the SW limb of the Sun before the total eclipse began. An analysis of CATE data from 17:22 to 17:39 UT maps the spatial distribution of coronal flow velocities from about 1.2 to 2.1 RSun, and shows the CME material accelerates from about 0 to 200 km s−1 across this part of the corona. This CME is observed by LASCO C2 at 3.1–13 RSun with a constant speed of 254 km s−1. The CATE and LASCO observations are not fit by either constant acceleration nor spatially uniform velocity change, and so the CME acceleration mechanism must produce variable acceleration in this region of the corona.
- 12 December 2019
- Published by IOP Publishing in Publications of the Astronomical Society of the Pacific
- Vol. 132 (1007) , 014201
Open AccessAcceleration of Coronal Mass Ejection Plasma in the Low Corona as Measured by the Citizen CATE Experiment
The citizen Continental-America Telescopic Eclipse (CATE) Experiment was a new type of citizen science experiment designed to capture a time sequence of white-light coronal observations during totality from 17:16 to 18:48 UT on 2017 August 21. Using identical instruments the CATE group imaged the inner corona from 1 to 2.1 RSun with 1.″43 pixels at a cadence of 2.1 s. A slow coronal mass ejection (CME) started on the SW limb of the Sun before the total eclipse began. An analysis of CATE data from 17:22 to 17:39 UT maps the spatial distribution of coronal flow velocities from about 1.2 to 2.1 RSun, and shows the CME material accelerates from about 0 to 200 km s−1 across this part of the corona. This CME is observed by LASCO C2 at 3.1–13 RSun with a constant speed of 254 km s−1. The CATE and LASCO observations are not fit by either constant acceleration nor spatially uniform velocity change, and so the CME acceleration mechanism must produce variable acceleration in this region of the corona.
- Open Access
- 1 November 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-15
Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling
Dissemination of tumour cells to the bone marrow is an early event in breast cancer, however cells may lie dormant for many years before bone metastases develop. Treatment for bone metastases is not curative, therefore new adjuvant therapies which prevent the colonisation of disseminated cells into metastatic lesions are required. There is evidence that cancer stem cells (CSCs) within breast tumours are capable of metastasis, but the mechanism by which these colonise bone is unknown. Here, we establish that bone marrow-derived IL1β stimulates breast cancer cell colonisation in the bone by inducing intracellular NFkB and CREB signalling in breast cancer cells, leading to autocrine Wnt signalling and CSC colony formation. Importantly, we show that inhibition of this pathway prevents both CSC colony formation in the bone environment, and bone metastasis. These findings establish that targeting IL1β-NFKB/CREB-Wnt signalling should be considered for adjuvant therapy to prevent breast cancer bone metastasis.
- 1 November 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-15
Open AccessMicroenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling
Dissemination of tumour cells to the bone marrow is an early event in breast cancer, however cells may lie dormant for many years before bone metastases develop. Treatment for bone metastases is not curative, therefore new adjuvant therapies which prevent the colonisation of disseminated cells into metastatic lesions are required. There is evidence that cancer stem cells (CSCs) within breast tumours are capable of metastasis, but the mechanism by which these colonise bone is unknown. Here, we establish that bone marrow-derived IL1β stimulates breast cancer cell colonisation in the bone by inducing intracellular NFkB and CREB signalling in breast cancer cells, leading to autocrine Wnt signalling and CSC colony formation. Importantly, we show that inhibition of this pathway prevents both CSC colony formation in the bone environment, and bone metastasis. These findings establish that targeting IL1β-NFKB/CREB-Wnt signalling should be considered for adjuvant therapy to prevent breast cancer bone metastasis.
- 1 September 2019
- Published by Elsevier in European Urology Focus
- Vol. 5 (5) , 831-841
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer
- 1 September 2019
- Published by Elsevier in European Urology Focus
- Vol. 5 (5) , 831-841
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e66
EphA2 ligand independent activation underpins PTEN related metastatic migration and poor outcome in prostate cancer
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e66
EphA2 ligand independent activation underpins PTEN related metastatic migration and poor outcome in prostate cancer
- 20 February 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (6_suppl) , 220
Correlation of primary biopsy mutational landscape to pre-docetaxel LDH for prediction of docetaxel therapeutic response.
220 Background: There is a lack of biomarkers to predict docetaxel response. Here we assess the potential of pre-treatment LDH, associated to the mutational background of the primary biopsy taken prior to 1st line therapy with ADT, to predict docetaxel response in the castrate resistant setting. Methods: Clinical and associated primary biopsy targeted next-generation sequencing data from matched training (n = 150) and test (n = 120) sets of retrospective progressive mCRPC patients (diagnosed 1996-2006) treated with docetaxel therapy were analyzed. LDH thresholds were determined and validated on the training and test sets respectively. Clinico-pathological associations with LDH were assessed using student t-test, Wilcoxon test and Chi-square test and predictive value of LDH determined by linear regression analysis for PSA and radiologic response. Time to event outcomes (PFS & OS) was evaluated by Kaplan-Meier. Meta-analysis of LDH association with DNA repair genes in the MSKCC and SU2C/PCF was conducted using cBioPortal Results: Using pre-docetaxel serum LDH of ≥450U/L as a prognostic threshold (AUC:0.75 (SD 0.054, 95% CI, 0.650–0.864, P < 0.001)) patients with LDH ≥450U/L were poorer PSA responders, with shorter PFS (213 vs 372 days, HR 1.876 (95% CI, 1.289-2.730)) and OS (362 vs 563 days, HR 1.630 (95% CI, 1.127-2.357)). LDH was also an independent surrogate marker for prediction of poor radiologic response and survival following docetaxel chemotherapy (P = 0.043). Genomic analysis showed that patients with LDH ≥450U/L (9/14 (64.3%)) have a higher tumour mutational burden (TMB) at the point of primary pre-ADT biopsy (mean, 46.2 vs 6.2 mutations/MB; p = 0.129) and that they were more likely to have DNA repair gene mutation(s) (BRCA1/2, ATM, CHEK2 and Fanconi’s anemia gene). Meta-analysis of the large MSKCC and the SU2C-PCF patient genomic databases confirmed the positive correlation between the LDH gene LDHA and PARP1 gene (r = 0.667, p < 0.01) expression and expression of other DNA repair genes. Conclusions: High pre-treatment serum LDH coupled with mutations in the DNA repair pathway in primary pre-ADT biopsy correlates with poor docetaxel response and overall survival in the castrate resistant state.
- 20 February 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (6_suppl) , 220
Correlation of primary biopsy mutational landscape to pre-docetaxel LDH for prediction of docetaxel therapeutic response.
220 Background: There is a lack of biomarkers to predict docetaxel response. Here we assess the potential of pre-treatment LDH, associated to the mutational background of the primary biopsy taken prior to 1st line therapy with ADT, to predict docetaxel response in the castrate resistant setting. Methods: Clinical and associated primary biopsy targeted next-generation sequencing data from matched training (n = 150) and test (n = 120) sets of retrospective progressive mCRPC patients (diagnosed 1996-2006) treated with docetaxel therapy were analyzed. LDH thresholds were determined and validated on the training and test sets respectively. Clinico-pathological associations with LDH were assessed using student t-test, Wilcoxon test and Chi-square test and predictive value of LDH determined by linear regression analysis for PSA and radiologic response. Time to event outcomes (PFS & OS) was evaluated by Kaplan-Meier. Meta-analysis of LDH association with DNA repair genes in the MSKCC and SU2C/PCF was conducted using cBioPortal Results: Using pre-docetaxel serum LDH of ≥450U/L as a prognostic threshold (AUC:0.75 (SD 0.054, 95% CI, 0.650–0.864, P < 0.001)) patients with LDH ≥450U/L were poorer PSA responders, with shorter PFS (213 vs 372 days, HR 1.876 (95% CI, 1.289-2.730)) and OS (362 vs 563 days, HR 1.630 (95% CI, 1.127-2.357)). LDH was also an independent surrogate marker for prediction of poor radiologic response and survival following docetaxel chemotherapy (P = 0.043). Genomic analysis showed that patients with LDH ≥450U/L (9/14 (64.3%)) have a higher tumour mutational burden (TMB) at the point of primary pre-ADT biopsy (mean, 46.2 vs 6.2 mutations/MB; p = 0.129) and that they were more likely to have DNA repair gene mutation(s) (BRCA1/2, ATM, CHEK2 and Fanconi’s anemia gene). Meta-analysis of the large MSKCC and the SU2C-PCF patient genomic databases confirmed the positive correlation between the LDH gene LDHA and PARP1 gene (r = 0.667, p < 0.01) expression and expression of other DNA repair genes. Conclusions: High pre-treatment serum LDH coupled with mutations in the DNA repair pathway in primary pre-ADT biopsy correlates with poor docetaxel response and overall survival in the castrate resistant state.
- Open Access
- 11 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (24) , 38264-38275
Lipid degradation promotes prostate cancer cell survival
Lipid degradation promotes prostate cancer cell survival
- 11 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (24) , 38264-38275
Open AccessLipid degradation promotes prostate cancer cell survival
Lipid degradation promotes prostate cancer cell survival
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1073-e1074
Identification of tumour-specific biomarkers associated with serum lactate dehydrogenase levels for predicting clinical responses to docetaxel chemotherapy in mCRPC
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1073-e1074
Identification of tumour-specific biomarkers associated with serum lactate dehydrogenase levels for predicting clinical responses to docetaxel chemotherapy in mCRPC